Health
MEPs supportive of draft Biotech report, but divisions over incentives remain
The European Parliament's first debate on its draft Biotech Act report showed broad political support for strengthening Europe's biotechnology sector, while exposing disagreements over how best to boost innovation, streamline clinical trials and incentivize investment.
Presenting their joint report, co-rapporteurs Wouter Beke MEP (EPP, Belgium) from the Industry, Research and Energy (ITRE) committee and Vytenis Andriukaitis MEP (S&D, Lithuania) from the Public Health (SANT) committee argued the legislation should position Europe as a global biotechnology leader by linking competitiveness with better patient access.
Beke warned that Europe is steadily losing ground to the United States and China in venture capital, clinical trials, manufacturing and commercialization, arguing that biotechnology has become "deeply geopolitical"....

Share this article:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
-
Kashmir4 days agoKashmir's 9,765 missing women and girls demand international attention
-
Israel2 days agoEU foreign ministers to discuss options for restricting trade with Israeli communities in Judea and Samaria
-
Animal welfare4 days agoNew EU strategy must help farmers move toward a more humane food system
-
Mexico4 days agoEU-Mexico: While others build walls, Europe builds bridges
